Literature DB >> 1479402

Prolactin secreting pituitary carcinoma.

T Petterson1, I A MacFarlane, J M MacKenzie, M D Shaw.   

Abstract

A man with a prolactin secreting pituitary carcinoma was treated by surgery and radiotherapy. Persistent hyperprolactinaemia partially responded to oral bromocriptine for four years. Serum prolactin then rose considerably with rapid, invasive tumour recurrence. Cytotoxic chemotherapy halted tumour progression for twelve months before fatal spread throughout the brain. Failure to normalise serum prolactin with bromocriptine may precede an aggressive course in patients with prolactinoma.

Entities:  

Mesh：

Substances：

Year:  1992        PMID： 1479402      PMCID： PMC1015342          DOI： 10.1136/jnnp.55.12.1205

Source DB:  PubMed          Journal:  J Neurol Neurosurg Psychiatry        ISSN： 0022-3050            Impact factor:   10.154


  11 in total

Review 1.  Management of prolactinomas.

Authors:  D Cunnah; M Besser
Journal:  Clin Endocrinol (Oxf)       Date:  1991-03       Impact factor: 3.478

2.  The diagnosis of carcinoma of the pituitary gland.

Authors:  A B KING
Journal:  Bull Johns Hopkins Hosp       Date:  1951-11

Review 3.  Prolactinomas.

Authors:  A Grossman; G M Besser
Journal:  Br Med J (Clin Res Ed)       Date:  1985-01-19

4.  Multiple intracranial metastases from a prolactin secreting pituitary tumour.

Authors:  R W Gasser; G Finkenstedt; F Skrabal; K Twerdy; V Grunert; U Mayr; H Frommhold; D Zur Nedden; J Feichtinger; F Hofstaedter
Journal:  Clin Endocrinol (Oxf)       Date:  1985-01       Impact factor: 3.478

5.  Metastatic prolactin-secreting pituitary adenoma.

Authors:  H S U; C Johnson
Journal:  Hum Pathol       Date:  1984-01       Impact factor: 3.466

6.  An intracranial metastasis from a PRL secreting pituitary tumour.

Authors:  D L Cohen; J V Diengdoh; D G Thomas; R L Himsworth
Journal:  Clin Endocrinol (Oxf)       Date:  1983-03       Impact factor: 3.478

Review 7.  Malignant prolactinomas.

Authors:  E A Popovic; J R Vattuone; K H Siu; I Busmanis; M J Pullar; J Dowling
Journal:  Neurosurgery       Date:  1991-07       Impact factor: 4.654

8.  Malignant prolactinoma with multiple intracranial metastases studied with positron emission tomography.

Authors:  C Muhr; M Bergström; P O Lundberg; M Hartman; K Bergström; L Pellettieri; B Långström
Journal:  Neurosurgery       Date:  1988-02       Impact factor: 4.654

9.  Dramatic and rapid shrinkage of a massive invasive prolactinoma with bromocriptine: a case report.

Authors:  R N Clayton; J Webb; D A Heath; P J Dunn; E B Rolfe; A D Hockley
Journal:  Clin Endocrinol (Oxf)       Date:  1985-05       Impact factor: 3.478

10.  Prolactin cell carcinoma of the pituitary. Clinicopathologic, immunohistochemical, and ultrastructural study of a case with cranial and extracranial metastases.

Authors:  B W Scheithauer; R V Randall; E R Laws; K T Kovacs; E Horvath; M D Whitaker
Journal:  Cancer       Date:  1985-02-01       Impact factor: 6.860
View more
  11 in total

Review 1.  Malignant pituitary tumours.

Authors:  G A Kaltsas; A B Grossman
Journal:  Pituitary       Date:  1998-04       Impact factor: 4.107

Review 2.  Clinical review: Pituitary carcinoma: difficult diagnosis and treatment.

Authors:  Anthony P Heaney
Journal:  J Clin Endocrinol Metab       Date:  2011-09-28       Impact factor: 5.958

Review 3.  Corticotrophic pituitary carcinoma with cervical metastases: case series and literature review.

Authors:  Frederick Yoo; Edward C Kuan; Anthony P Heaney; Marvin Bergsneider; Marilene B Wang
Journal:  Pituitary       Date:  2018-06       Impact factor: 4.107

Review 4.  Pituitary carcinoma: report of an exceptional case and review of the literature.

Authors:  C Pichard; S Gerber; M Laloi; M Kujas; S Clemenceau; D Ponvert; E Bruckert; G Turpin
Journal:  J Endocrinol Invest       Date:  2002-01       Impact factor: 4.256

Review 5.  Progression of a Nelson's adenoma to pituitary carcinoma; a case report and review of the literature.

Authors:  S A Kemink; P Wesseling; G F Pieters; A A Verhofstad; A R Hermus; A G Smals
Journal:  J Endocrinol Invest       Date:  1999-01       Impact factor: 4.256

Review 6.  Progression on metastatic neuroendocrine carcinoma from a recurrent prolactinoma: a case report.

Authors:  M Sironi; G Cenacchi; L Cozzi; G Tonnarelli; M Iacobellis; D Treré; A Assi
Journal:  J Clin Pathol       Date:  2002-02       Impact factor: 3.411

7.  Temozolomide treatment for aggressive pituitary tumors: correlation of clinical outcome with O(6)-methylguanine methyltransferase (MGMT) promoter methylation and expression.

Authors:  Zachary M Bush; Janina A Longtine; Tracy Cunningham; David Schiff; John A Jane; Mary Lee Vance; Michael O Thorner; Edward R Laws; M Beatriz S Lopes
Journal:  J Clin Endocrinol Metab       Date:  2010-07-28       Impact factor: 5.958

8.  An Institutional Experience of Tumor Progression to Pituitary Carcinoma in a 15-Year Cohort of 1055 Consecutive Pituitary Neuroendocrine Tumors.

Authors:  Omalkhaire M Alshaikh; Sylvia L Asa; Ozgur Mete; Shereen Ezzat
Journal:  Endocr Pathol       Date:  2019-06       Impact factor: 3.943

9.  Aggressive and malignant prolactin pituitary tumors: pathological diagnosis and patient management.

Authors:  Ilyess Zemmoura; Anne Wierinckx; Alexandre Vasiljevic; Michel Jan; Jacqueline Trouillas; Patrick François
Journal:  Pituitary       Date:  2013-12       Impact factor: 4.107

Review 10.  Approach to the Treatment of a Patient with an Aggressive Pituitary Tumor.

Authors:  Andrew L Lin; Mark T A Donoghue; Sharon L Wardlaw; T Jonathan Yang; Lisa Bodei; Viviane Tabar; Eliza B Geer
Journal:  J Clin Endocrinol Metab       Date:  2020-12-01       Impact factor: 5.958
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.